MX2021011913A - Composiciones de virus inactivado y formulaciones de vacunas contra el zika. - Google Patents

Composiciones de virus inactivado y formulaciones de vacunas contra el zika.

Info

Publication number
MX2021011913A
MX2021011913A MX2021011913A MX2021011913A MX2021011913A MX 2021011913 A MX2021011913 A MX 2021011913A MX 2021011913 A MX2021011913 A MX 2021011913A MX 2021011913 A MX2021011913 A MX 2021011913A MX 2021011913 A MX2021011913 A MX 2021011913A
Authority
MX
Mexico
Prior art keywords
inactivated virus
vaccine formulations
virus compositions
zika vaccine
pharmaceutically acceptable
Prior art date
Application number
MX2021011913A
Other languages
English (en)
Inventor
Michael Johnson
Sushma Kommareddy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2021011913A publication Critical patent/MX2021011913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención hace referencia a una composición líquida de virus inactivado que comprende: un virus del Zika completo e inactivado, al menos un tampón aceptable desde un punto de vista farmacéutico con una concentración de al menos aproximadamente 6.5 mM, y opcionalmente un poliol, en la que dicho al menos un tampón aceptable desde un punto de vista farmacéutico no comprende iones fosfato y vacunas derivadas de estos.
MX2021011913A 2019-05-08 2020-04-08 Composiciones de virus inactivado y formulaciones de vacunas contra el zika. MX2021011913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962845024P 2019-05-08 2019-05-08
PCT/US2020/027154 WO2020226831A1 (en) 2019-05-08 2020-04-08 Inactivated virus compositions and zika vaccine formulations

Publications (1)

Publication Number Publication Date
MX2021011913A true MX2021011913A (es) 2021-12-15

Family

ID=70465537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011913A MX2021011913A (es) 2019-05-08 2020-04-08 Composiciones de virus inactivado y formulaciones de vacunas contra el zika.

Country Status (14)

Country Link
US (1) US20220211836A1 (es)
EP (1) EP3965811A1 (es)
JP (1) JP2022533550A (es)
KR (1) KR20220007077A (es)
CN (1) CN113939311A (es)
AR (1) AR118881A1 (es)
AU (1) AU2020269164B2 (es)
BR (1) BR112021019845A2 (es)
CA (1) CA3137652A1 (es)
IL (1) IL288002A (es)
MX (1) MX2021011913A (es)
SG (1) SG11202110975XA (es)
TW (1) TW202108168A (es)
WO (1) WO2020226831A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193736A (en) 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
JP7443233B2 (ja) 2017-11-30 2024-03-05 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活性化する方法及び関連する方法
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
EP2179744B1 (en) 2004-09-09 2010-12-01 Novartis Vaccines and Diagnostics GmbH Decreasing potential latrogenic risks associated with influenza vaccines
CN108601825B (zh) * 2015-07-16 2023-06-20 巴拉特生物技术国际有限公司 疫苗组合物
BR112018012873A2 (pt) * 2015-12-23 2018-12-04 Valneva Austria Gmbh vacina de vírus zika
CN105749268B (zh) * 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
US11033615B2 (en) * 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
MY193736A (en) * 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
JP7443233B2 (ja) * 2017-11-30 2024-03-05 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活性化する方法及び関連する方法
CN108187036A (zh) * 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗

Also Published As

Publication number Publication date
CA3137652A1 (en) 2020-11-12
AR118881A1 (es) 2021-11-10
BR112021019845A2 (pt) 2022-02-15
SG11202110975XA (en) 2021-10-28
AU2020269164A1 (en) 2021-11-25
KR20220007077A (ko) 2022-01-18
TW202108168A (zh) 2021-03-01
US20220211836A1 (en) 2022-07-07
CN113939311A (zh) 2022-01-14
IL288002A (en) 2022-01-01
WO2020226831A1 (en) 2020-11-12
JP2022533550A (ja) 2022-07-25
EP3965811A1 (en) 2022-03-16
AU2020269164B2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
PH12019500954A1 (en) Vaccine against porcine parvovirus
PH12020550051A1 (en) Glp-1 compositions and uses thereof
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
SI1954308T1 (sl) Stabilizatorji za liofilizirana cepiva
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
WO2017156511A8 (en) Live attenuated zika virus vaccine
PH12019501320A1 (en) Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
MY191895A (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
WO2018097603A3 (ko) 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
MY153290A (en) Multivalent avian influenza vaccines
GEP20237539B (en) Formulations of dengue virus vaccine compositions
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
PH12021550441A1 (en) Modified pedv spike protein
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2022003754A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y fluoruro.
NZ756582A (en) Immunogenic compositions against influenza